🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

138 results for “Bristol” Clear

  1. A Phase 1/2 Randomized Trial of BMS-986012 in Combination with Platinum and Etoposide as First-line Therapy in Extensive-Stage Small Cell Lung Cancer

    Bristol-Myers Squibb Australia Pty Ltd

    Extensive-Stage Small Cell Lung Cancer

    phase 2 other active

    1 trial

  2. BBP-398, CETUXIMAB, ADAGRASIB

    Bristol-Myers Squibb Australia Pty Ltd

    Oncology, NSCLC and CRC

    phase 2 small molecule active

    1 trial

  3. BET-Inhibitor, Jakavi 5 mg tablets, Jakavi 10 mg tablets, Jakavi 15 mg tablets, FEDRATINIB

    Bristol-Myers Squibb Australia Pty Ltd

    DIPSS-Intermediate or High Risk Myelofibrosis

    phase 2 small molecule active

    1 trial

  4. BMS-986165

    Bristol-Myers Squibb

    Granulomatous Colitis

    phase 2 small molecule terminated

    1 trial

  5. BMS-986165

    Bristol-Myers Squibb

    Lupus Nephritis

    phase 2 small molecule terminated

    1 trial

  6. BMS-986165

    Bristol-Myers Squibb

    Systemic Lupus Erythematosus

    phase 2 small molecule completed

    1 trial

  7. BMS-986466

    Bristol-Myers Squibb

    Advanced Solid Tumors

    phase 2 small molecule terminated

    1 trial

  8. BMS-986470, BMS-986470, N/A, BMS-986470

    Bristol-Myers Squibb Australia Pty Ltd

    Sickle Cell Disease

    phase 2 small molecule active

    1 trial

  9. BMS-986504

    Bristol-Myers Squibb

    Solid Tumors

    phase 2 small molecule active

    1 trial

  10. BMS-986517

    Bristol-Myers Squibb Australia Pty Ltd

    Advanced Solid Tumors

    phase 2 small molecule active

    1 trial

  11. BMS-986523, BMS-986523

    Bristol-Myers Squibb Australia Pty Ltd

    Advanced Solid Tumor Malignancies

    phase 2 small molecule active

    1 trial

  12. BMS-986525, OPDIVO 10 mg/mL concentrate for solution for infusion.

    Bristol-Myers Squibb Australia Pty Ltd

    Relapsed/Refractory Small Cell Lung Cancer

    phase 2 small molecule active

    1 trial

  13. BNT327 50 mg ml, BNT327 20 mg ml, IPILIMUMAB, ATEZOLIZUMAB, ATEZOLIZUMAB, BEVACIZUMAB, Ipilimumab

    Bristol-Myers Squibb Australia Pty Ltd

    Advanced or unresectable Hepatocellular Carcinoma (HCC)

    phase 2 small molecule active

    1 trial

  14. CISPLATIN, Ipilimumab, PACLITAXEL, Nivolumab Subcutaneous, CARBOPLATIN, PEMETREXED

    Bristol-Myers Squibb Australia Pty Ltd

    Non-small cell lung cancer (NSCLC)

    phase 2 small molecule active

    1 trial

  15. CISPLATIN, OPDIVO 10 mg/mL concentrate for solution for infusion., PACLITAXEL, anti-NKG2A mAb, CARBOPLATIN, PEMETREXED DISODIUM

    Bristol-Myers Squibb Australia Pty Ltd

    Non-small Cell Lung Cancer

    phase 2 small molecule active

    1 trial

  16. Caelyx pegylated liposomal 2 mg/ml concentrate for solution for infusion, PACLITAXEL, TOPOTECAN, farletuzumab ecteribulin

    Bristol-Myers Squibb Australia Pty Ltd

    Platinum-resistant High-grade Serous Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

    phase 2 small molecule active

    1 trial

  17. DASATINIB, Dasatinib, dasatinib, dasatinib

    Bristol-Myers Squibb Australia Pty Ltd

    Children and Adolescents with Newly Diagnosed Chronic Phase CML or with Ph+ Leukemias Resistant to or Intolerant to Imatinib

    phase 2 small molecule active

    1 trial

  18. DEXAMETHASONE, DEXAMETHASONE, LENALIDOMIDE, Empliciti 400 mg powder for concentrate for solution for infusion., LENALIDOMIDE, LENALIDOMIDE, LENALIDOMIDE

    Bristol-Myers Squibb Australia Pty Ltd

    Multiple Myeloma

    phase 2 small molecule active

    1 trial

  19. Dasatinib

    Bristol-Myers Squibb

    Chronic Myeloid Leukemia

    phase 2 small molecule completed

    1 trial

  20. Deucravacitinib

    Bristol-Myers Squibb

    Alopecia Areata

    phase 2 small molecule terminated

    1 trial

  21. FDC Nivolumab + Relatlimab + rHuPH20 Injection, Nivolumab/Relatlimab, OPDIVO 10 mg/mL concentrate for solution for infusion., Nivolumab Subcutaneous

    Bristol-Myers Squibb Australia Pty Ltd

    Melanoma

    phase 2 small molecule active

    1 trial

  22. Florquinitau F-18, Sodium Chloride, PRX005

    Bristol-Myers Squibb Australia Pty Ltd

    Early Alzheimer’s Disease

    phase 2 small molecule active

    1 trial

  23. MRTX1719

    Bristol-Myers Squibb Australia Pty Ltd

    Advanced or Metastatic Non-small Cell Lung Cancer

    phase 2 small molecule active

    1 trial

  24. Nivo 240 mg and Rela 80 mg per vial, OPDIVO 10 mg/mL concentrate for solution for infusion., Relatlimab

    Bristol-Myers Squibb Australia Pty Ltd

    Neoplasms by site

    phase 2 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources